EXAS Exact Sciences Corporation Stock Quote

EXAS [NASD]

Healthcare | Diagnostics & Research | USA

Index	-	P/E	-	EPS (ttm)	-2.20	Insider Own	0.70%	Shs Outstand	150.16M	Perf Week	1.84%
Market Cap	24.13B	Forward P/E	-	EPS next Y	-1.30	Insider Trans	-21.67%	Shs Float	-	Perf Month	6.35%
Income	-333.80M	PEG	-	EPS next Q	-0.28	Inst Own	93.10%	Short Float	-	Perf Quarter	50.59%
Sales	1.32B	P/S	18.27	EPS this Y	55.40%	Inst Trans	4.54%	Short Ratio	4.87	Perf Half Y	53.47%
Book/sh	15.56	P/B	9.64	EPS next Y	56.10%	ROA	-8.00%	Target Price	154.07	Perf Year	62.73%
Cash/sh	7.98	P/C	18.81	EPS next 5Y	-	ROE	-13.80%	52W Range	35.25 - 152.87	Perf YTD	13.22%
Dividend	-	P/FCF	-	EPS past 5Y	12.50%	ROI	-1.90%	52W High	-1.88%	Beta	1.51
Dividend %	-	Quick Ratio	6.00	Sales past 5Y	244.80%	Gross Margin	75.50%	52W Low	325.52%	ATR	6.29
Employees	4110	Current Ratio	6.40	Sales Q/Q	86.70%	Oper. Margin	-33.40%	RSI (14)	64.36	Volatility	3.46% 4.50%
Optionable	Yes	Debt/Eq	0.68	EPS Q/Q	-368.20%	Profit Margin	-25.30%	Rel Volume	0.68	Prev Close	148.07
Shortable	Yes	LT Debt/Eq	0.68	Earnings	Oct 29 AMC	Payout	-	Avg Volume	2.00M	Price	150.00
Recom	1.50	SMA20	7.97%	SMA50	14.81%	SMA200	50.84%	Volume	1,369,303	Change	1.30%

Oct-29-20

Downgrade

UBS

Buy → Neutral

$125 → $140

Oct-28-20

Downgrade

Citigroup

Buy → Neutral

$120 → $140

Oct-08-20

Resumed

BTIG Research

Buy

$140

Apr-02-20

Initiated

Evercore ISI

Outperform

$70

Jan-10-20

Resumed

BTIG Research

Buy

$127

Jan-07-20

Initiated

Citigroup

Buy

$120

Dec-13-19

Initiated

Dougherty & Company

Buy

$120

Nov-15-19

Initiated

Stifel

Buy

Oct-17-19

Reiterated

BofA/Merrill

Buy

$130 → $135

Oct-01-19

Resumed

Craig Hallum

Buy

$127

Sep-26-19

Initiated

Oppenheimer

Outperform

$130

Feb-26-19

Upgrade

Goldman

Neutral → Buy

$85 → $120

Oct-09-18

Initiated

UBS

Buy

Sep-05-18

Resumed

The Benchmark Company

Hold

Aug-13-18

Reiterated

Canaccord Genuity

Buy

$62 → $65

Apr-03-18

Upgrade

BTIG Research

Neutral → Buy

Jan-29-18

Initiated

Goldman

Neutral

$51

Jan-08-18

Reiterated

The Benchmark Company

Buy

$60 → $65

Nov-13-17

Downgrade

Robert W. Baird

Outperform → Neutral

$56

Nov-01-17

Downgrade

BTIG Research

Buy → Neutral

Jan-14-21 12:34PM	15 Best Undervalued Stocks to Buy Now Insider Monkey
12:16PM	Exact Sciences (EXAS) Posts Solid Preliminary Q4 Testing Revenues Zacks
Jan-13-21 02:45PM	Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology PR Newswire
07:00AM	Sidoti Virtual Investor Conference ACCESSWIRE
06:30AM	Apogee Enterprises Announces Seven Percent Increase to Quarterly Dividend Business Wire
Jan-12-21 02:45PM	New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard® PR Newswire
12:48PM	Exact Sciences Scores Relative Strength Rating Upgrade; Hits Key Threshold Investor's Business Daily
08:32AM	Exact Sciences (EXAS) Soars: Stock Adds 9.8% in Session Zacks
Jan-11-21 11:01AM	Why Exact Sciences Stock Is Soaring Today Motley Fool +9.84%
Jan-10-21 07:30PM	Exact Sciences Announces Preliminary Fourth Quarter 2020 Results PR Newswire
Jan-08-21 07:00AM	Why The Covid Pandemic Will Be A Boon For These Health Care Stocks Investor's Business Daily
Jan-05-21 08:25AM	Exact Sciences Completes Acquisition of Thrive Earlier Detection, Creating a Leader in Blood-Based, Multi-Cancer Screening PR Newswire
06:30AM	Apogee Enterprises Reports Grant of Inducement Award Business Wire
Dec-28-20 06:00AM	Exact Sciences to participate in J.P. Morgan Healthcare Conference PR Newswire
Dec-26-20 05:17PM	These Are The 5 Best Stocks To Buy And Watch Now Investor's Business Daily
Dec-22-20 04:42PM	Is EXAS A Good Stock To Buy According To Hedge Funds? Insider Monkey
05:41AM	Earnings Beat: Apogee Enterprises, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models Simply Wall St.
Dec-21-20 05:10PM	Dow Jones Futures: Stimulus Deal Vote Due After Stock Market Rally, Apple, AMD, Nio, Uber Rebound From Key Level; Tesla Stock Is Biggest S&P 500 Loser Investor's Business Daily
10:08AM	Exact Sciences Breaks Out Investor's Business Daily Video
06:30AM	Apogee Enterprises Appoints Ty R. Silberhorn as CEO Business Wire
Dec-18-20 07:15AM	Apogee Enterprises, Inc. to Host Earnings Call ACCESSWIRE
06:30AM	Apogee Enterprises Reports Fiscal 2021 Third-quarter Results Business Wire
Dec-17-20 11:45PM	A Look At The Fair Value Of Apogee Enterprises, Inc. (NASDAQ:APOG) Simply Wall St. +6.84%
04:44PM	This IBD Stock Of The Day Hasn't Broken Out Yet But It's Actionable Now Investor's Business Daily
10:17AM	Exact Sciences Sets Up For Breakout Investor's Business Daily Video
Dec-11-20 06:23PM	Should I Buy Apogee Enterprises, Inc. (APOG)? Insider Monkey
09:00AM	New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice PR Newswire
Dec-09-20 12:30PM	Is EXACT Sciences Corp (EXAS) a Smart Long-term Buy? Insider Monkey
09:00AM	RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer PR Newswire
09:00AM	RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer CNW Group
Dec-03-20 06:30AM	Apogee Enterprises to Report Fiscal 2021 Third Quarter Financial Results Business Wire +5.03%
Nov-23-20 06:00AM	Exact Sciences to participate in December investor conference PR Newswire
Nov-14-20 12:05PM	Stock Market Rally At Highs, But Who Will Lead? Google, Microsoft, Visa, JD.com, Moderna Coronavirus Vaccine In Focus Investor's Business Daily
08:08AM	Forget Apple! Buy These 2 High-Growth Stocks Instead Motley Fool
Nov-13-20 11:11AM	Exact Sciences Looking Tight Investor's Business Daily Video
08:30AM	Wild Ride For Illumina Stock Shows Promise, Challenge Of Multi-Cancer Blood Tests Investor's Business Daily
Nov-08-20 09:06PM	Here's Why Exact Sciences Jumped 21.5% in October Motley Fool
Nov-02-20 10:45AM	Exact Sciences (EXAS) Loses 5.6% Despite Beating Q3 Earnings Zacks
06:00AM	Exact Sciences to participate in November investor conferences PR Newswire
Oct-28-20 12:16PM	Investing Isn't an 'Exact Science' but the Charts Do Look Good TheStreet.com
10:24AM	Exact Sciences Stock Cut by Citi to Neutral on Valuation TheStreet.com
07:41AM	The Daily Biotech Pulse: Sanofi-GlaxoSmithKline To Supply 200M Doses To COVID-19 Vaccine Alliance, Gilead Earnings, Biodesix Debuts Benzinga
Oct-27-20 04:35PM	Exact Sciences Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45 PR Newswire +23.04%
03:03PM	Why Exact Sciences $2.15 Billion Deal Has Investors Excited About Cancer-Screening Technology Barrons.com
02:09PM	Here's Why Exact Sciences Stock Rocketed Higher Today Motley Fool
12:44PM	Exact Sciences Soars on $2.15 Billion Deal for Testing Firm Bloomberg
11:26AM	Exact Sciences Surges on $2.5 Billion Deal to Buy Thrive TheStreet.com
10:29AM	Exact Sciences's Debt Overview Benzinga
10:25AM	Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates Zacks
09:55AM	Looking Into Exact Sciences's Return On Capital Employed Benzinga
08:19AM	Exact Sciences to buy cancer-screening firm Thrive Earlier Detection in $2.15 bln deal Reuters
07:54AM	Imagine Holding Exact Sciences (NASDAQ:EXAS) Shares While The Price Zoomed 978% Higher Simply Wall St.
07:14AM	Exact Sciences to acquire Thrive Earlier Detection Corp. in cash and stock deal worth up to $2.15 billion MarketWatch
07:10AM	Exact Sciences Announces Entry into Agreements to Sell $869 Million of Common Stock in Registered Direct Offering PR Newswire
07:01AM	Exact Sciences Announces Third Quarter 2020 Results PR Newswire
07:00AM	Exact Sciences To Acquire Thrive Earlier Detection, Becoming A Leader In Blood-Based, Multi-Cancer Screening PR Newswire
Oct-26-20 09:01PM	Was The Smart Money Right About Crowding Into EXACT Sciences Corporation (EXAS)? Insider Monkey
Oct-22-20 12:34PM	Analysts Estimate Exact Sciences (EXAS) to Report a Decline in Earnings: What to Look Out for Zacks +7.51%
Oct-12-20 09:00AM	Exact Sciences Introduces the Oncotype MAP Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer PR Newswire
Oct-10-20 03:00PM	Stocks That Would Have Made You Rich Today GOBankingRates
Oct-09-20 06:00AM	Exact Sciences schedules third quarter 2020 earnings call PR Newswire
Oct-08-20 09:00AM	Exact Sciences Stock Could Sprint Higher in the Weeks Ahead TheStreet.com
Oct-07-20 06:11AM	Exact Sciences and Pfizer Extend and Amend Cologuard® Promotion Agreement PR Newswire
Oct-04-20 06:27AM	Got $500? Here Are 2 Stocks That Could Soar Motley Fool
Oct-01-20 02:22PM	7 Diagnostic and Genomic Stocks Storming Into October Zacks
Sep-29-20 07:27AM	Is Exact Sciences a Good Healthcare Stock to Buy Now? Motley Fool
Sep-28-20 08:53AM	3 Healthcare Stocks That Jumped Higher Last Week Motley Fool
Sep-25-20 09:22AM	ROCE Insights For Exact Sciences Benzinga
Sep-24-20 03:37PM	Why Exact Sciences Stock Skyrocketed Today Motley Fool +26.85%
02:47PM	Exact Sciences Jumps as Company Presents at Cowen Event TheStreet.com
02:35PM	Exact Sciences Stock Surges on Cancer Blood-Test Results Barrons.com
12:11PM	Why Exact Sciences Stock Is Trading Higher Today Benzinga
Sep-21-20 04:27PM	Illumina Announces $8 Billion Acquisition Of Former Cancer-Testing Spinoff Grail Investor's Business Daily -5.11%
11:25AM	EXACT Sciences (EXAS) Has Fallen 28% in Last One Year, Underperforms Market Insider Monkey
Sep-17-20 06:00AM	Exact Sciences to participate in Cowen Liquid Biopsy Summit PR Newswire
Sep-07-20 12:52PM	Hedge Funds Never Been This Bullish On EXACT Sciences Corporation (EXAS) Insider Monkey
Sep-01-20 04:05PM	Exact Sciences to participate in September investor conference PR Newswire
Aug-29-20 11:31AM	Why Is Exact Sciences (EXAS) Down 25.3% Since Last Earnings Report? Zacks
Aug-01-20 04:03AM	Exact Sciences (EXAS) Q2 2020 Earnings Call Transcript Motley Fool
Jul-31-20 12:13PM	Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines Zacks
11:13AM	Why Exact Sciences pivoted into COVID-19 testing Yahoo Finance Video
06:38AM	Exact Sciences Beats Q2 Estimates Despite a COVID-19 Drag Motley Fool
Jul-30-20 06:30PM	Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates Zacks
Jul-29-20 08:40AM	Should You Buy Exact Sciences (EXAS) Ahead of Earnings? Zacks
Jul-23-20 12:32PM	Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Should You Buy? Zacks
11:30AM	Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year? Zacks
Jul-17-20 08:00AM	How Genetic Testing For Cancer Could Create A $51 Billion U.S. Market Investor's Business Daily
Jul-12-20 12:00PM	Did Hedge Funds Make The Right Call On XACT Sciences Corporation (EXAS) ? Insider Monkey
Jul-08-20 07:45AM	An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued Simply Wall St. +6.21%
06:00AM	Exact Sciences schedules annual meeting, second quarter 2020 earnings call PR Newswire
Jun-16-20 03:09PM	Robinhood traders could learn from this growth-stock investor whos beaten indexes by a wide margin for years MarketWatch
08:00AM	Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients PR Newswire
Jun-05-20 11:31AM	Why Is Exact Sciences (EXAS) Up 2.4% Since Last Earnings Report? Zacks
Jun-03-20 09:49AM	Edited Transcript of EXAS earnings conference call or presentation 6-May-20 9:00pm GMT Thomson Reuters StreetEvents
01:15AM	Hedge Funds Cashing Out Of EXACT Sciences Corporation (EXAS) Insider Monkey
May-29-20 08:00AM	Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020 PR Newswire
May-26-20 06:00AM	Exact Sciences to participate in June investor conferences PR Newswire
May-17-20 06:46AM	Could Exact Sciences Be a Millionaire-Maker Stock? Motley Fool
May-12-20 03:10PM	Pivoting From Poop: How Exact Sciences is Turning to Option #2 Yahoo Finance Video
10:23AM	Is Exact Sciences Stock a Buy? Motley Fool

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Conroy Kevin T	President and CEO	Jan 04	Sale	128.74	31,814	4,095,734	825,704	Jan 07 09:05 AM
Zanotti Katherine S	Director	Dec 14	Sale	132.06	20,000	2,641,182	21,907	Dec 14 06:15 PM
Conroy Kevin T	President and CEO	Dec 01	Sale	124.56	30,577	3,808,660	857,518	Dec 02 06:28 PM
Conroy Kevin T	President and CEO	Nov 02	Sale	121.11	32,819	3,974,738	888,095	Nov 03 04:49 PM
Conroy Kevin T	President and CEO	Oct 01	Sale	103.55	27,425	2,839,829	920,914	Oct 02 05:54 PM
Hoof Torsten	General Manager, International	Sep 24	Option Exercise	41.53	4,401	182,774	6,418	Sep 28 04:33 PM
Hoof Torsten	General Manager, International	Sep 24	Sale	80.00	4,401	352,080	2,017	Sep 28 04:33 PM
Conroy Kevin T	President and CEO	Sep 01	Sale	75.03	19,927	1,495,123	948,339	Sep 02 04:32 PM
Hoof Torsten	General Manager, International	Aug 19	Option Exercise	43.40	1,516	65,794	9,981	Aug 21 04:31 PM
Hoof Torsten	General Manager, International	Aug 19	Sale	84.90	7,964	676,144	2,017	Aug 21 04:31 PM
Hoof Torsten	General Manager, International	Aug 17	Option Exercise	0.00	2,551	0	8,465	Aug 19 04:15 PM
Conroy Kevin T	President and CEO	Aug 03	Sale	93.80	25,198	2,363,560	968,266	Aug 04 05:18 PM
Zanotti Katherine S	Director	Jul 31	Option Exercise	8.52	21,029	179,167	62,936	Aug 04 04:54 PM
LEVANGIE DANIEL J	Director	Jul 31	Option Exercise	9.30	9,865	91,699	24,881	Aug 04 04:58 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Jul 31	Option Exercise	21.68	6,638	143,912	75,861	Aug 04 05:02 PM
Carey Thomas D.	Director	Jul 31	Option Exercise	9.24	15,620	144,329	52,492	Aug 04 05:21 PM
Carey Thomas D.	Director	Jul 31	Sale	94.00	30,620	2,878,280	21,872	Aug 04 05:21 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Jul 31	Sale	93.83	37,500	3,518,771	38,361	Aug 04 05:02 PM
LEVANGIE DANIEL J	Director	Jul 31	Sale	94.00	9,865	927,310	15,016	Aug 04 04:58 PM
Zanotti Katherine S	Director	Jul 31	Sale	94.00	21,029	1,976,726	41,907	Aug 04 04:54 PM
Doyle James Edward	Director	Jul 31	Sale	94.00	2,539	238,666	32,459	Aug 04 04:45 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Jul 29	Sale	95.58	8,746	835,943	69,223	Jul 30 08:18 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Jul 28	Option Exercise	94.81	18,750	1,777,688	77,969	Jul 30 08:18 PM
Zanotti Katherine S	Director	Jul 28	Sale	96.13	1,164	111,895	41,907	Jul 30 06:49 PM
Stenhouse Mark	President, Cologuard	Apr 03	Sale	56.69	11,948	677,332	29,571	Apr 06 04:41 PM
Stenhouse Mark	President, Cologuard	Apr 02	Option Exercise	0.00	25,000	0	41,519	Apr 06 04:41 PM
Doyle James Edward	Director	Feb 28	Sale	77.54	2,000	155,080	32,440	Mar 03 07:20 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 28	Sale	80.17	2,383	191,045	58,578	Mar 02 07:15 PM
Conroy Kevin T	President and CEO	Feb 28	Sale	80.17	9,750	781,658	992,963	Mar 02 07:13 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 27	Option Exercise	0.00	5,025	0	61,141	Mar 02 07:15 PM
Conroy Kevin T	President and CEO	Feb 27	Option Exercise	0.00	20,575	0	1,002,713	Mar 02 07:13 PM
Conroy Kevin T	President and CEO	Feb 27	Sale	80.27	13,875	1,113,746	982,138	Feb 28 04:36 PM
Stenhouse Mark	President, Cologuard	Feb 27	Sale	80.27	1,051	84,364	16,519	Feb 28 04:39 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 27	Sale	80.27	1,627	130,599	56,116	Feb 28 04:37 PM
Conroy Kevin T	President and CEO	Feb 26	Option Exercise	0.00	29,337	0	996,013	Feb 28 04:36 PM
Stenhouse Mark	President, Cologuard	Feb 26	Option Exercise	0.00	3,262	0	17,570	Feb 28 04:39 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 26	Option Exercise	0.00	3,436	0	57,743	Feb 28 04:37 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 25	Sale	85.11	4,910	417,890	54,307	Feb 26 05:13 PM
Conroy Kevin T	President and CEO	Feb 25	Sale	85.11	18,115	1,541,768	966,676	Feb 26 05:11 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 24	Option Exercise	0.00	9,300	0	59,217	Feb 26 05:13 PM
Conroy Kevin T	President and CEO	Feb 24	Option Exercise	0.00	34,325	0	984,791	Feb 26 05:11 PM
Cole G Bradley	General Manager - Diagnostics	Feb 19	Option Exercise	35.77	17,356	620,776	37,550	Feb 21 04:58 PM
ORVILLE JACOB A	General Manager, New Ventures	Feb 19	Sale	100.68	1,153	116,084	2,495	Feb 20 05:55 PM
Cole G Bradley	General Manager - Diagnostics	Feb 19	Sale	100.00	27,356	2,735,600	10,194	Feb 21 04:58 PM
ORVILLE JACOB A	General Manager, New Ventures	Feb 18	Option Exercise	0.00	3,648	0	3,648	Feb 20 05:55 PM
Hoof Torsten	General Manager, International	Feb 15	Option Exercise	0.00	2,091	0	5,914	Mar 27 04:15 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience